---
title: "Bernstein Sticks to Its Buy Rating for AstraZeneca (AZN)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/301106518.md"
description: "In a report released today, Justin Smith from Bernstein maintained a Buy rating on AstraZeneca, with a price target of £198.00. Smith covers the Healthcare sector, focusing on stocks such as AstraZeneca, Roche Holding AG, and GlaxoSmithKline. According to TipRanks, Smith has an average return of 8.5% and a 57.14% success rate on recommended stocks. In addition to Bernstein, AstraZeneca also received a Buy from Citi’s Graham Parry in a report issued yesterday. However, on September 29, Deutsche Bank maintained a Hold rating on AstraZeneca (LSE: AZN)."
datetime: "2026-10-07T06:15:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/301106518.md)
  - [en](https://longbridge.com/en/news/301106518.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/301106518.md)
generator: "portal-rs"
---

# Bernstein Sticks to Its Buy Rating for AstraZeneca (AZN)

In a report released today, Justin Smith from Bernstein maintained a Buy rating on AstraZeneca, with a price target of £198.00.

Smith covers the Healthcare sector, focusing on stocks such as AstraZeneca, Roche Holding AG, and GlaxoSmithKline. According to TipRanks, Smith has an average return of 8.5% and a 57.14% success rate on recommended stocks. 

In addition to Bernstein, AstraZeneca also received a Buy from Citi’s Graham Parry in a report issued yesterday. However, on September 29, Deutsche Bank maintained a Hold rating on AstraZeneca (LSE: AZN).

### Related Stocks

- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)
- [GSK.UK](https://longbridge.com/en/quote/GSK.UK.md)
- [C.US](https://longbridge.com/en/quote/C.US.md)
- [DB.US](https://longbridge.com/en/quote/DB.US.md)
- [GSK.US](https://longbridge.com/en/quote/GSK.US.md)
- [RHHBY.US](https://longbridge.com/en/quote/RHHBY.US.md)

## Related News & Research

- [AstraZeneca Adds New Indication for Ultomiris Drug in Rare Kidney Disease](https://longbridge.com/en/news/302656212.md)
- [AstraZeneca's Ultomiris Gets FDA Accelerated Approval As First C5 Inhibitor For IgAN](https://longbridge.com/en/news/302673006.md)
- [AstraZeneca (AZN) Tezspire Phase III Success in EoE](https://longbridge.com/en/news/302426434.md)
- [AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial](https://longbridge.com/en/news/302425900.md)
- [Insitro, AstraZeneca Sign AI Drug Discovery Deal](https://longbridge.com/en/news/301978211.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**